AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15017529
Drug: Angiotensin-Converting Enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors)
Trial: 31760711
Drug: Angiotensin Receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin Receptor Blockers (ARBs)
Trial: 15017529
Drug: Combination antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVE COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antihypertensive therapy including ACE inhibitors or ARBs
Trial: 9322717
Drug: Antiseptic or
RxNorm normalized name: Antiseptic Oral Rinse
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiseptic or antibiotic lavage
Trial: 2719236
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural morphine
Trial: 11323346
Drug: Succinylcholine (SUC)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (SUC) 1 mg/kg
Trial: 12447292
Drug: Water instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water instillation (500 to 1000 mL) at the beginning of the procedure
Trial: 2697729
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplementation
Trial: 31382981
Drug: Cefuroxime 1500
RxNorm normalized name: cefuroxime 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1500 mg intravenously prior to skin incision
Trial: 31382981
Drug: Cefuroxime 1500
RxNorm normalized name: cefuroxime 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1500 mg intravenously after clamping of the umbilical cord
Trial: 29477817
Drug: Serum uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum uric acid levels >7.2 mg/dl
Trial: 29477817
Drug: Serum uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum uric acid levels ≥7 mg/dl
Trial: 28925134
Drug: Longxue Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longxue Tongluo capsule (two capsules each time, three times daily for 4 weeks)
Trial: 28925134
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules each time, three times daily for 4 weeks)
Trial: 28925134
Drug: Longxue Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longxue Tongluo capsule
Trial: 23072975
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) for social anxiety disorder
Trial: 340390
Drug: Teorema (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teorema (210 mg/day for 21 days)
Trial: 340390
Drug: Indometacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (150 mg/day for 21 days)
Trial: 340390
Drug: Indometacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (75 mg/day for 21 days)
Trial: 21747013
Drug: Nurse-administered behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered behavioral management
Trial: 21747013
Drug: Nurse- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse- and physician-administered medication management
Trial: 16393297
Drug: Laxative (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative (polyethylene glycol 3350 oral solution)
Trial: 16393297
Drug: Laxative and
RxNorm normalized name: DOCUSATE SODIUM 50 mg / SENNOSIDES 8.6 mg ORAL TABLET [Laxative and Stool Softener]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative and tegaserod
Trial: 10193418
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy initiation
Trial: 8525072
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (triamcinolone 200 mg i.v. within 4 h after trauma, followed by 3 x 40 mg/day i.v. for 4 days, and 3 x 20 mg/day i.v. for a further 4 days)
Trial: 8525072
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (injections without active drug)
Trial: 8525072
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (in patients with focal lesion and Glasgow Coma Score < 8)
Trial: 6989226
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OC) users
Trial: 6989226
Drug: Sucrose load
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose load (1 g/kg)
Trial: 6989226
Drug: Peak levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak levels of glucose and insulin
Trial: 26329790
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg (day 1)
Trial: 19085343
Drug: Aliskiren/HCT 300/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/HCT 300/25 mg
Trial: 17342794
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (child's usual treatment)
Trial: 22763312
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib
Trial: 3178925
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg paracetamol
Trial: 31164265
Drug: Letrozole (L)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (L)
Trial: 22712469
Drug: DHEA replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA replacement therapy (50 mg day(-1))
Trial: 16632234
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro insulin sliding scale
Trial: 12810472
Drug: Intranasal furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal furosemide
Trial: 12810472
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate
Trial: 8979159
Drug: Oral supplement
RxNorm normalized name: Healios Oral Supplement Unflavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement of ascorbate, alpha‐tocopherol and beta‐carotene
Trial: 1350882
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitrate therapy (patch removed at night, mean patch-off period 10 hours)
Trial: 1350882
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal nitrate therapy (10 mg/24 hours)
Trial: 22714699
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 (monoclonal antibody inhibitor of PCSK9)
Trial: 20624650
Drug: Subcutaneous mite
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP)
Trial: 20624650
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) therapy alone
Trial: 12088809
Drug: 1.0 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 L/min fresh gas flow
Trial: 12088809
Drug: 2.0 L/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 L/min fresh gas flow
Trial: 2616932
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A followed by Treatment B
Trial: 2616932
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B followed by Treatment A
Trial: 319967
Drug: Pimozide 9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide 9.6 mg
Trial: 319967
Drug: Fluphenazine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine 12.5 mg
Trial: 30138668
Drug: Dupilumab 200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200/300 mg every 2 weeks
Trial: 18591555
Drug: Topotecan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2) on day 1 and 600 mg/m(2) on day 8 every 3 weeks
Trial: 15982747
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/day (increased to 20 mg/day after 4 weeks)
Trial: 17288677
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/day
Trial: 12162936
Drug: Combined ACE
RxNorm normalized name: ACE INHIBITORS, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ACE inhibitor plus ARB therapy
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents with antiplatelet drugs (250 mg ticlopidine and 100 mg aspirin)
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents in phase I
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents in phase II
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents in phase III
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents in phase IV
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents (all phases combined)
Trial: 8565157
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents (phase I)
Trial: 27494705
Drug: Multisystemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic Therapy
Trial: 20015219
Drug: Intermittent interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART)
Trial: 17875076
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg/day) for 20 days
Trial: 16132897
Drug: Parenteral lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral lipid‐based nutrition (L group)
Trial: 16132897
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral glucose‐based nutrition (G group)
Trial: 2112080
Drug: Chinese-made levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese-made levonorgestrel tablets (0.75 mg)
Trial: 7323106
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg intramuscular procaine penicillin daily for 14 days
Trial: 7323106
Drug: 1080 mg
RxNorm normalized name: magaldrate 1080 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1080 mg intramuscular procaine penicillin daily for 14 days
Trial: 7323106
Drug: 1440 mg
RxNorm normalized name: ZINC OXIDE 1440 mg in 8 g TOPICAL POWDER [bareMinerals Original Foundation Broad Spectrum SPF 15 Deepest Deep 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1440 mg intramuscular procaine penicillin daily for 14 days
Trial: 28390934
Drug: Quadrivalent inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent inactivated influenza vaccine (IIV4)
Trial: 31426731
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg for 6 months
Trial: 29079602
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual supplemented by a booklet on self-management
Trial: 26475266
Drug: TRK-100STP 120
RxNorm normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK-100STP 120 μg/day
Trial: 26475266
Drug: TRK-100STP 240
RxNorm normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK-100STP 240 μg/day
Trial: 22111658
Drug: Alfentanil 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 7.5 μg/kg
Trial: 20184225
Drug: Triflusal oral
RxNorm normalized name: triflusal Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal oral solution (600 mg)
Trial: 21327422
Drug: Triflusal capsules
RxNorm normalized name: triflusal
DrugBank: Triflusal (DB08814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal capsules (600 mg)
Trial: 19736358
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control (WLC) plus treatment as usual
Trial: 10437612
Drug: Adjuvant intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant intra-arterial chemotherapy (mitomycin C 8 mg/m2 on day 1 and 5-fluorouracil 800 mg/m2 on days 1-5 for four courses at 4-week intervals) in group A (14 patients)
Trial: 19256155
Drug: Lactitol (LA)
RxNorm normalized name: Lactitol
DrugBank: Lactitol (DB12942)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactitol (LA) 29 g/day
Trial: 12734151
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug three times a day for two weeks before surgery
Trial: 12734151
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg) three times a day for two weeks before surgery
Trial: 29737805
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement containing Lactobacillus acidophilus LA‐5, Bifidobacterium BB‐12, Streptococcus Thermophilus STY‐31, and Lactobacillus delbrueckii bulgaricus LBY‐27
Trial: 27689551
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS (2 mA for 20 minutes) + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Trial: 27689551
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS + Occupational Therapy (OT) for 45 minutes/day (10 sessions for 2 weeks)
Trial: 22227576
Drug: CHESS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHESS plus therapy
Trial: 20357371
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 1.5 units/kg
Trial: 20357371
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 1.0 units/kg
Trial: 16043735
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg OD) + Metformin (1.5-3.0 mg/day)
Trial: 16043735
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Metformin (1.5-3.0 mg/day)
Trial: 31179546
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (three doses: 0, 2, 6 months)
Trial: 26935044
Drug: Chloroquine 250
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 250 mg orally for the first 12 weeks
Trial: 15763039
Drug: Description of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Description of a treatment as new
Trial: 15763039
Drug: Doctor's uncertainty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor's uncertainty about the best treatment
Trial: 9713140
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg, single dose)
Trial: 31461575
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy
Trial: 24176804
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy‐cognitive
Trial: 24176804
Drug: Pre‐treatment AS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐treatment AS dimensions
Trial: 12924753
Drug: Promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (25 mg)
Trial: 16685054
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (20 mg/d)
Trial: 9625272
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg [14C]-labelled Losigamone
Trial: 9625272
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of each of the unlabelled enantiomers
Trial: 16338269
Drug: Calcium-channel blockers
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel blockers
Trial: 24298801
Drug: Modified step‐back
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified step‐back technique with Gates‐Glidden bur (Group G)
Trial: 10436310
Drug: Low-dose n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose n-3 fatty acids (330 mg/day docosahexaenoic acid and 630 mg/day eicosapentanoic acid)
Trial: 7788823
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (OND) 0.1 mg.kg-1
Trial: 7788823
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (OND)
Trial: 2177861
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 5000 UI twice daily
Trial: 15653010
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 80 mg twice daily for 12 months
Trial: 10660871
Drug: Maltodextrin (CHO)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (CHO) at a dosage of 0.7 g.kg body mass‐1
Trial: 8403177
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral diazepam
Trial: 21148030
Drug: cinacalcet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinacalcet plus low‐dose vitamin D sterols (30‐180 mg/day and ≤ 2 μg paricalcitol equivalent/dialysis)
Trial: 21148030
Drug: flexible vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flexible vitamin D therapy
Trial: 17715422
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (6 mg/24 h)
Trial: 19527191
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (12 mg/24 h)
Trial: 19527191
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (6 mg/24 h and 12 mg/24 h)
Trial: 12225701
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of ethanol
Trial: 9447863
Drug: Physostigmine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.04 mg/kg)
Trial: 30643009
Drug: Meperidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.5 mg/kg)
Trial: 8523623
Drug: Oxandrolone (OX)
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone (OX) plus a high caloric food supplement
Trial: 2191938
Drug: Nimodipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (10-20 mg t.i.d., according to body weight)
Trial: 375121
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g L-dopa + 200 mg carbodopa + 300 mg imipramine orally for 30 days
Trial: 375121
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg apomorphine s.c. + 2 g L-dopa + 200 mg carbodopa per os daily for 15 days
Trial: 31351492
Drug: Modified minimally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified minimally invasive surgical therapy (M-MIST)
Trial: 29771062
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray with 2.3% hypertonic saline
Trial: 2908300
Drug: Carvedilol 25mg
RxNorm normalized name: CARVEDILOL 25MG TAB
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 25mg twice daily
Trial: 2908300
Drug: Metoprolol 50mg
RxNorm normalized name: HCTZ 25/METOPROLOL 50MG TAB
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50mg twice daily